MDH2 S246 phosphorylation protects mitochondria against hypoxia/reoxygenation injury due to acetate/lactate metabolism.

Fuente: PubMed
Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Marquez, Jubert, Park, Nammi, Garcia, Maria Victoria Faith, Flores, Jessa, Shimizu, Ippei, Kim, Hyoung Kyu, Han, Jin
Format: Artículo científico
Sprache:en
Veröffentlicht: The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2026
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1868266102700638208
author Marquez, Jubert
Park, Nammi
Garcia, Maria Victoria Faith
Flores, Jessa
Shimizu, Ippei
Kim, Hyoung Kyu
Han, Jin
author_facet Marquez, Jubert
Park, Nammi
Garcia, Maria Victoria Faith
Flores, Jessa
Shimizu, Ippei
Kim, Hyoung Kyu
Han, Jin
Marquez, Jubert
Park, Nammi
Garcia, Maria Victoria Faith
Flores, Jessa
Shimizu, Ippei
Kim, Hyoung Kyu
Han, Jin
collection PubMed - marine biology
contents MDH2 S246 phosphorylation protects mitochondria against hypoxia/reoxygenation injury due to acetate/lactate metabolism. Marquez, Jubert Park, Nammi Garcia, Maria Victoria Faith Flores, Jessa Shimizu, Ippei Kim, Hyoung Kyu Han, Jin Ischemic cardiomyopathy (ICM) is characterized by impaired myocardial function resulting from reduced coronary blood flow, resulting in heart failure. Emerging evidence from proteomic studies indicates that ischemic preconditioning confers cardioprotection against ICM through the regulation of mitochondrial proteins. Proteomic analyses have identified phosphorylation in mitochondrial proteins, including malate dehydrogenase 2 (MDH2), as mediators of cardioprotective mechanisms. However, the mechanism by which MDH2 phosphorylation contributes to cardioprotection in cardiovascular diseases remains poorly understood. This study investigates the role of MDH2 phosphorylation, particularly at S246, in regulating cardiac function. Analysis of patients with dilated cardiomyopathy indicated no significant change in expression, similar to a trend observed in ischemic patient data. Considering that a previous proteomic analysis of ischemic preconditioned rat hearts indicated phosphorylation at S246, we analyzed the functional role of this phosphorylation by introducing S246A phosphomutation. S246A phosphomutation significantly decreased MDH2 activity, accompanied by an increased accumulation of acetate and lactate as demonstrated by metabolomics. S246A phosphomutation also lowers mitochondrial membrane potential and ATP production. Under hypoxia/reoxygenation (H/R) conditions, S246A phosphomutation downregulates mitochondrial biogenesis and fusion proteins such as PGC1α and OPA1. Overall, these findings suggest that MDH2 phosphorylation at S246 is important in protecting against H/R injury through mitochondrial function regulation and activation of metabolic pathways. This discovery establishes a potential therapeutic strategy and a clear direction for drug development to specifically address conditions such as ICM.
format Artículo científico
id pubmed_41496511
institution PubMed
language en
publishDate 2026
publisher The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology
record_format pubmed
spellingShingle MDH2 S246 phosphorylation protects mitochondria against hypoxia/reoxygenation injury due to acetate/lactate metabolism.
Marquez, Jubert
Park, Nammi
Garcia, Maria Victoria Faith
Flores, Jessa
Shimizu, Ippei
Kim, Hyoung Kyu
Han, Jin
MDH2 S246 phosphorylation protects mitochondria against hypoxia/reoxygenation injury due to acetate/lactate metabolism. Marquez, Jubert Park, Nammi Garcia, Maria Victoria Faith Flores, Jessa Shimizu, Ippei Kim, Hyoung Kyu Han, Jin Ischemic cardiomyopathy (ICM) is characterized by impaired myocardial function resulting from reduced coronary blood flow, resulting in heart failure. Emerging evidence from proteomic studies indicates that ischemic preconditioning confers cardioprotection against ICM through the regulation of mitochondrial proteins. Proteomic analyses have identified phosphorylation in mitochondrial proteins, including malate dehydrogenase 2 (MDH2), as mediators of cardioprotective mechanisms. However, the mechanism by which MDH2 phosphorylation contributes to cardioprotection in cardiovascular diseases remains poorly understood. This study investigates the role of MDH2 phosphorylation, particularly at S246, in regulating cardiac function. Analysis of patients with dilated cardiomyopathy indicated no significant change in expression, similar to a trend observed in ischemic patient data. Considering that a previous proteomic analysis of ischemic preconditioned rat hearts indicated phosphorylation at S246, we analyzed the functional role of this phosphorylation by introducing S246A phosphomutation. S246A phosphomutation significantly decreased MDH2 activity, accompanied by an increased accumulation of acetate and lactate as demonstrated by metabolomics. S246A phosphomutation also lowers mitochondrial membrane potential and ATP production. Under hypoxia/reoxygenation (H/R) conditions, S246A phosphomutation downregulates mitochondrial biogenesis and fusion proteins such as PGC1α and OPA1. Overall, these findings suggest that MDH2 phosphorylation at S246 is important in protecting against H/R injury through mitochondrial function regulation and activation of metabolic pathways. This discovery establishes a potential therapeutic strategy and a clear direction for drug development to specifically address conditions such as ICM.
title MDH2 S246 phosphorylation protects mitochondria against hypoxia/reoxygenation injury due to acetate/lactate metabolism.
url https://pubmed.ncbi.nlm.nih.gov/41496511/